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A 60-year-old man with hypertrophic obstructive cardiomyopathy (HOCM) was implanted
dual-chamber ICD for the purpose of both the left ventricular outﬂow tract (LVOT) gradient
reduction by ventricular pacing and the primary prevention of ventricular tachyarrhythmia.
Because the LVOT gradient reduction and improvement of symptoms by pacing were
insuﬃcient, however, a new pacing lead was inserted in the right ventricular apex at a
diﬀerent position 1.5 cm away from the site of the deﬁbrillation lead, and the LVOT gradient
greatly declined from 108 to 30mmHg. This DDD pacing was continued over seven years. On
this occasion, he was referred to our hospital because of battery depletion, and a cardiac
catheterization study was performed after ICD replacement. The LVOT gradient was
10mmHg in sinus rhythm. After administration of isoproterenol (0:02), the gradient was
increased to 92mmHg in sinus rhythm. DDD pacing using a newly placed ventricular pacing
lead signiﬁcantly decreased the gradient to 36mmHg. This case study indicated that DDD
pacing from a suitable location in the right ventricular apex caused a marked early reduction
in the LVOT gradient, and at long-term follow up a further signiﬁcant eﬀect was obtained,
also in sinus rhythm.
(J Arrhythmia 2011; 27: 226–230)
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Introduction
Hypertrophic cardiomyopathy (HCM) is a dis-
order characterized by the presence of otherwise
unexplained ventricular hypertrophy. The prevalence
of HCM in the general population is estimated to be
as high as 0.2%, and about 25% of cases present with
septal hypertrophy, leading to dynamic obstruction
of the left ventricular outﬂow tract (LVOT),1) which
is called hypertrophic obstructive cardiomyopathy
(HOCM). A pressure gradient at the LVOT of more
than 50mmHg is a powerful predictor of an adverse
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outcome. There are several types of treatment in
patients with HOCM whose condition is refractory
to medical therapy, such as septal myotomy and
myectomy,2) transcoronary alcohol ablation of the
interventricular septum,3) and dual-chamber pacing.
Recently, the beneﬁcial eﬀect of dual-chamber
(DDD) pacing to reduce the LVOT gradient has
been well documented in patients with HOCM.4–7)
It has not been established, however, whether the
initial favorable eﬀect of DDD pacing is maintained
long term. In addition, there are few reports about
the LVOT gradient reduction measured in sinus
rhythm at late follow-up. Here, we report a HOCM
case in which DDD pacing from a suitable site in the
right ventricular apex decreased the LVOT gradient
greatly with implantable cardioverter deﬁbrillator
(ICD) implantation, and continuous DDD pacing
over seven years signiﬁcantly decreased its level
further, also in sinus rhythm.
Case Report
Clinical Course
In November, 1999, a 60-year-old man was seen
at another hospital because of palpitations, and
paroxysmal atrial ﬁbrillation and HOCM were
diagnosed on echocardiography. The pressure gra-
dient at the LVOT was 58mmHg at rest. In April and
July, 2002, he was admitted to our hospital with
pulmonary edema, although he had been taking
cibenzoline 300mg, verapamil 240mg, and atenolol
50mg. At that time, the thickness of the interven-
tricular septum was 20mm on echocardiography,
and a cardiac catheterization study revealed that
LVOT gradient was 108mmHg and ventricular
tachycardia was induced by ventricular extrastimulus
testing. His condition was refractory to medical
therapy, and accordingly on August 30, 2002, a dual-
chamber ICD was implanted intravenously to reduce
the LVOT gradient by ventricular pacing, as well as
for the primary prevention of ventricular tachyar-
rhythmia. The atrial pacing lead was located in the
right atrial appendage, and the deﬁbrillation lead
was located in the right ventricular apex. However,
the LVOT gradient reduction and improvement of
symptoms were insuﬃcient by pacing under any
atrio-ventricular delay conditions. On September 13,
2002, a new pacing lead was inserted in the right
ventricular apex at a diﬀerent position 1.5 cm away
from the site of the deﬁbrillation lead, and as a result
the LVOT gradient greatly declined from 108 to
30mmHg under the conditions of DDD pacing rate
70/min, sensed AV delay 80ms and paced AV delay
120ms. The newly inserted pacing lead played the
role of pacing and the formerly inserted deﬁbrillation
lead only the role of treating the ventricular
tachyarrhythmia. DDD pacing was continued and
the patient’s condition remained good over seven
years, and on this occasion, he was referred again to
our hospital for ICD replacement because of battery
depletion.
Findings on admission
The patient had no family history of HCM. Blood
pressure was 126/60mmHg and pulse rate was
60 beats/min and regular. Physical examination
revealed a mid systolic heart murmur of Levine
2/6 along the left sternal border. Brain natriuretic
peptide (BNP) level was 237 pg/ml. Twelve-lead
electrocardiogram showed p-tracking ventricular
pacing. Chest X-ray showed the ICD implanted in
the upper left anterior portion of his chest, with an
atrial pacing lead, a ventricular deﬁbrillation lead
and a ventricular pacing lead (Figure 1). Echo-
cardiography revealed asymmetric septal hypertro-
phy and narrowing of the left ventricular outﬂow
tract, and the thickness of the septum was 20mm,
which showed no remarkable change from that seen
before ICD implantation. The LVOT gradient was
15mmHg during DDD pacing and did not change
after 30 minutes in sinus rhythm.
Cardiac Catheterization study
Accordingly, after replacement of the ICD, a
Figure 1 Chest X-ray.
Chest X-ray showed ICD implanted in the upper left anterior
portion of the chest with an atrial pacing lead, a ventricular
deﬁbrillation lead and a ventricular pacing lead.
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cardiac catheterization study was performed under
the conditions of DDD pacing rate 70/min, sensed
AV delay 80ms and paced AV delay 120ms. The
left ventricular apex pressure using a multipurpose
catheter and aortic pressure using a pigtail catheter
were recorded simultaneously and the pressure
diﬀerence was used as a surrogate endpoint of the
LVOT gradient. At ﬁrst, DDD pacing was turned oﬀ,
and observation was continued over 60 minutes. The
LVOT gradient was 10mmHg in sinus rhythm, and
changed little during DDD mode pacing (Figure 2).
After administration of isoproterenol (0:02), max-
imum heart rate was increased to 80/min, and the
LVOT gradient was increased to 92mmHg in sinus
rhythm. During DDD pacing using the deﬁbrillation
lead for ventricular pacing, the gradient decreased to
62mmHg, and by use of the additionally inserted
ventricular pacing lead, it signiﬁcantly decreased to
36mmHg (Figure 3).
Discussion
HOCM and effect of pacing
It has been known for about 30 years that right
ventricular apex pacing can reduce the LVOT
gradient in HOCM. The M-PATHY study (Multi-
center Study of Pacing Therapy for Hypertrophic
Cardiomyopathy) involved 48 patients and showed a
reduction in the LVOT gradient in those with a DDD
pacemaker (from 82 to 48mmHg, P < 0:001),
which, however, was not associated with improve-
ment in functional capacity.6) The PIC (Pacing in
Cardiomyopathy) study involved 83 patients and
found that those patients randomized to receive
a DDD pacemaker had a signiﬁcant reduction in
LVOT gradient (from 72 to 29mmHg) and an
improvement in symptoms and functional capacity.7)
Megevand et al. have reported a study of DDD
pacemaker implantation in HOCM with long-term
follow up (up to 10 years):8) They found a statisti-
cally signiﬁcant reduction in LVOT gradient that
was maintained and more apparent over time (from
82 to 42mmHg early, and 32mmHg at late follow-
up). In the present HOCM patient, DDD pacing from
a suitable site in the right ventricular apex caused a
favorable reduction of LVOT gradient shortly after
ICD implantation. In addition, there was a further
signiﬁcant reduction of LVOT gradient in DDD
pacing and no recurrence of pulmonary edema over
seven years. DDD pacing caused long-term reduc-
tion of the LVOT gradient and improvement of





Figure 2 Simultaneous recordings of left ventricular apex
and aortic pressure.
A: In sinus rhythm, LVOT gradient was 10mmHg. B: During





Figure 3 Simultaneous recordings of left ventricular apex
and aortic pressure after administration of isoproterenol
(0:02).
A: In sinus rhythm, LVOT gradient was 92mmHg. B: During
DDD pacing of the deﬁbrillation lead, the gradient was 62mmHg.
C: During DDD pacing of the ventricular pacing lead, the gradient
was 36mmHg.
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ured this time in sinus rhythm was much lower than
that recorded just after ICD implantation. There are
few reports about LVOT gradient reduction meas-
ured in sinus rhythm at late follow-up.5) There are
some discrepancies between the acute and chronic
eﬀects of DDD pacing. Reduction of the LVOT
gradient decreases the pressure overload on the LV
wall and causes ventricular remodelling in relation
to asynchrony, bringing about a long-term eﬀect.
In the present case, however, regression of hyper-
trophy in the interventricular septum, which had
occurred as a result of remodeling, was not observed
after chronic DDD pacing. Fananapazir et al.
reported that there was no correlation between the
reduction in LVOT gradient and the change in LV
wall dimensions.5) Therefore, regression of hyper-
trophy may be not only secondary to the reduction of
LVOT gradient, but also a direct consequence of
pacing.
Mechanism of LVOT gradient reduction
There are several anatomical and functional
explanations for the development of LV outﬂow
obstruction, including Venturi forces,9) septal
bulge,9) elongation of the mitral leaﬂets,9) and
anterior displacement of the papillary muscles.10)
The mechanism by which DDD pacing may reduce
the LVOT gradient is not elucidated suﬃciently.
Some investigators have suggested that pacing may
inﬂuence myocardial perfusion11) and asynchronous
ventricular septal activation,4) produce paradoxical
movement of the septum4,5) or a negative inotropic
eﬀect,12) decrease mitral valve systolic anterior
motion,4,5) or increase end-systolic volume.12) Re-
cently, Hozumi et al. investigated the eﬀects of DDD
pacing on regional wall deformation, particularly of
the ventricular septum.13) In patients with HOCM,
DDD pacing led to myocardial lengthening, espe-
cially at the basal septum, as expressed in his paper
by the increase in echocardiographic peak strain and
SR after DDD pacing. These changes appeared to be
related to the degree of LVOT gradient reduction.
Isoproterenol administration
Isoproterenol has a -agonist property, which
increases contractility and decreases afterload. This
medical agent is useful in eliciting latent gradients in
patients with hypertrophic cardiomyopathy. In the
present patient at a cardiac catheterization study the
LVOT gradient was no more than 10mmHg in sinus
rhythm. After administration of isoproterenol, how-
ever, the LVOT gradient was increased to 92mmHg
in sinus rhythm. Isoproterenol better simulates the
hemodynamic eﬀect of exercise, and so the eﬀect of
LVOT gradient reduction was insuﬃcient during
exercise in the present patient. It is thought that DDD
pacing itself brings about LVOT gradient reduction
during exercise.
Location of pacing
In the present HOCM patient, pacing using an
additional ventricular pacing lead in addition to the
deﬁbrillation lead reduced the LVOT gradient to a
greater extent, although both leads were located in
the right ventricular apex. Matsumoto described a
case in which the extent of LVOT gradient reduction
diﬀered signiﬁcantly by a subtle diﬀerence of pacing
site in the right ventricular apex.14) One presumed
explanation for this is a change of paradoxical septal
movement. However, the detailed mechanism is
unknown, and further examinations by echocardio-
gram or myocardial scintigraphy are needed. In order
to obtain a good outcome by DDD pacing, it is
necessary to perform right ventriculography, deter-
mine the exact localization of the right ventricular
apex, and insert the ventricular lead at the right
ventricular apex with certainty. Considering the
good result in our case, it may be better to optimize
the pacing eﬀect by determining the pacing site in a
suitable place in the right ventricular apex.
Study limitation
We experienced a HOCM case in which DDD
pacing from a suitable location in the right ven-
tricular apex caused a marked early reduction in the
LVOT gradient, and additionally, a further signiﬁ-
cant eﬀect was obtained without ventricular pacing,
also in sinus rhythm at late follow up for about seven
years. However, we have not clariﬁed the following
study limitations. One possible limitation is that the
longer-term eﬀect of LVOT gradient reduction
at more than seven years might not be steadily
maintained, if ventricular pacing had been turned
oﬀ and follow-up continued for a while. The other
possible limitation is that prediction of a positive
hemodynamic eﬀect of DDD pacing has not been
clearly established yet. To evaluate the limitations of
our results, a further study with a large number of
patients in a long-term randomized trial is needed in
order to establish DDD pacemaker implantation as
highly eﬀective therapy for HOCM refractory to
medical therapy.
Summary
Our HOCM case with an excellent outcome
strongly suggests that DDD pacing from a suitable
site in the right ventricular apex causes a marked
early reduction in LVOT gradient, and at late follow
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up continuous DDD pacing over seven years
signiﬁcantly decreased the gradient further also in
sinus rhythm. We hope that our method described in
this paper might become standard treatment for
HOCM refractory to medical therapy.
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